MedTrace Logo

Study to Evaluate the Safety and Efficacy of CJ-30060 in Hypertensive Patients With Hyperlipidemia

NCT03536598 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 203

Last updated 2018-05-30

No results posted yet for this study

Summary

To evaluate the safety and efficacy of CJ-30060 compared with amlodipine/valsartan combination therapy and valsartan/rosuvastatin combination therapy in hypertensive patients with hyperlipidemia

Conditions

  • Hypertension With Hyperlipidemia

Interventions

DRUG

Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mg

DRUG

Amlodipine 10 mg + Valsartan 160 mg

DRUG

Valsartan 160 mg + Rosuvastatin 20 mg

Sponsors & Collaborators

  • HK inno.N Corporation

    lead INDUSTRY

Principal Investigators

  • Dong Ju Choi, Ph.D · Seoul National University Bundang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-14
Primary Completion
2017-09-04
Completion
2017-09-04

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03536598 on ClinicalTrials.gov